Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results